Targeting NPM1c by EAPB0503 activates the P53 pathway and downregulates HDM2, hence orchestrating the pro-apoptotic activity and inducing apoptosis in EAPB0503 treated NPM1c AML cells. This evidence concerns the gene TP53 and acute myeloid leukemia.